Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells

Authors: Dexiang Zhang, Yuedi Dai, Yuankun Cai, Tao Suo, Han Liu, Yueqi Wang, Zhijian Cheng, Houbao Liu

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Members of the Kruppel-like factor (KLF) family have been considered as the tumor suppressors for their inhibitory effects on cell proliferation. Dysregulation of KLF2, a member of KLF family, has been observed in various cancer types. However, its expression pattern and functions in the pancreatic ductal adenocarcinoma (PDAC) are unknown. In this study, we examined the expression of KLF2 in PDAC clinical samples and evaluated the functions of KLF2 in the progression of PDAC. KLF2 is shown to be downregulated in PDAC clinical samples and overexpression of KLF2 inhibits the growth, migration, and metastasis of PDAC cancer cells. KLF2 interacts with beta-catenin and negatively regulates the beta-catenin/TCF signaling. Taken together, this study suggests the suppressive functions of KLF2 in PDAC.
Literature
1.
2.
Kumaran S, Samantha KS, Halagowder D. Does beta-catenin cross-regulate NFkappaB signalling in pancreatic cancer and chronic pancreatitis? Pathobiology. 2015;82:28–35.CrossRefPubMed
3.
Xu W, Wang Z, Zhang W, et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway. Cancer Lett. 2015;356:613–27.CrossRefPubMed
4.
5.
Buttar NS, Fernandez-Zapico ME, Urrutia R. Key role of kruppel-like factor proteins in pancreatic cancer and other gastrointestinal neoplasias. Curr Opin Gastroenterol. 2006;22:505–11.CrossRefPubMed
6.
Turner J, Crossley M. Basic kruppel-like factor functions within a network of interacting haematopoietic transcription factors. Int J Biochem Cell Biol. 1999;31:1169–74.CrossRefPubMed
7.
Gao Y, Ding Y, Chen H, Chen H, Zhou J. Targeting kruppel-like factor 5 (KLF5) for cancer therapy. Curr Top Med Chem. 2015;15:699–713.CrossRefPubMed
8.
Lahiri SK, Zhao J. Kruppel-like factor 8 emerges as an important regulator of cancer. Am J Transl Res. 2012;4:357–63.PubMedPubMedCentral
9.
DiFeo A, Narla G, Martignetti JA. Emerging roles of kruppel-like factor 6 and kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med. 2009;76:557–66. New York.CrossRefPubMedPubMedCentral
10.
11.
Wang F, Zhu Y, Huang Y, et al. Transcriptional repression of WEE1 by kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene. 2005;24:3875–85.CrossRefPubMed
12.
Nie FQ, Sun M, Yang JS, et al. Long noncoding rna anril promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and p21 expression. Mol Cancer Ther. 2015;14:268–77.CrossRefPubMed
13.
Xie P, Tang Y, Shen S, et al. Smurf1 ubiquitin ligase targets kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells. Biochem Biophys Res Commun. 2011;407:254–9.CrossRefPubMed
14.
Xu TP, Liu XX, Xia R, et al. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene (E pubmed ahead of print). 2015.
15.
Xia R, Jin FY, Lu K, et al. Suz12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and e-cadherin. Tumour Biol (E pubmed ahead of print). 2015.
16.
Yin L, Wang JP, Xu TP, et al. Downregulation of kruppel-like factor 2 is associated with poor prognosis for nonsmall-cell lung cancer. Tumour Biol. 2015;36:3075–84.CrossRefPubMed
17.
Taniguchi H, Jacinto FV, Villanueva A, et al. Silencing of kruppel-like factor 2 by the histone methyltransferase ezh2 in human cancer. Oncogene. 2012;31:1988–94.CrossRefPubMed
18.
Wei Y, Chen G, You L, Zhao Y. Krupel-like factor 8 is a potential prognostic factor for pancreatic cancer. Chin Med J. 2014;127:856–9.PubMed
19.
Chakroborty D, Sarkar C, Yu H, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011;108:20730–5.CrossRefPubMedPubMedCentral
20.
Qiao F, Yao F, Chen L, et al. Kruppel-like factor 9 was down-regulated in esophageal squamous cell carcinoma and negatively regulated beta-catenin/TCF signaling. Molecular carcinogenesis (E pubmed ahead of print). 2015.
21.
Evans PM, Chen X, Zhang W, Liu C. KLF4 interacts with beta-catenin/TCF4 and blocks p300/CBP recruitment by beta-catenin. Mol Cell Biol. 2010;30:372–81.CrossRefPubMed
22.
Zhang W, Chen X, Kato Y, et al. Novel cross talk of kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor repression. Mol Cell Biol. 2006;26:2055–64.CrossRefPubMedPubMedCentral
Metadata
Title
KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells
Authors
Dexiang Zhang
Yuedi Dai
Yuankun Cai
Tao Suo
Han Liu
Yueqi Wang
Zhijian Cheng
Houbao Liu
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4053-3

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

The plasma lncRNA acting as fingerprint in non-small-cell lung cancer

Original Article

The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma

Original Article

RETRACTED ARTICLE: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults’ age groups and their association with prediction of poor prognosis in human osteosarcoma

Original Article

Expression analysis of four long noncoding RNAs in breast cancer

Original Article

ROS-mediated activation of JNK/p38 contributes partially to the pro-apoptotic effect of ajoene on cells of lung adenocarcinoma

Original Article

Enantiomeric CopA3 dimer peptide suppresses cell viability and tumor xenograft growth of human gastric cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits